Systemic Thrombolysis for Isolated Splenic Vein Thrombosis Secondary to Oral Contraceptives: A Case Report
DOI: https://doi.org/10.2147/ijwh.s462610
2024-05-14
International Journal of Women s Health
Abstract:Qianqian Li, &ast Ran Wang, &ast Xingshun Qi Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xingshun Qi, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, Liaoning Province, 110840, People's Republic of China, Tel +86-24-28897603, Fax +86-24-28851113, Email Isolated splenic vein thrombosis (ISVT) is a very rare venous thromboembolism in the absence of pancreatic diseases, which can cause acute abdominal pain and chronic left-side portal hypertension. Herein, we reported a 40-year-old female patient who developed ISVT after taking oral contraceptives. Anticoagulation with oral rivaroxaban was the first-line choice of therapy in this case. Since then, abdominal pain alleviated, but she did not achieve vessel recanalization. Thus, a 7-day systemic thrombolysis with urokinase was given. Abdominal pain disappeared, but ISVT was not significantly improved. During follow-up period, long-term anticoagulation with oral rivaroxaban was given. Collectively, this case indicates the possibility of oral contraceptives as a risk factor of ISVT as well as anticoagulation combined with systemic thrombolysis as a choice of treatment for ISVT. Certainly, long-term follow-up is necessary in this case. Keywords: splenic vein thrombosis, oral contraceptives, anticoagulation, rivaroxaban, thrombolysis Portal vein system thrombosis, which refers to complete or partial thrombotic obstruction of the main portal vein and/or its branches with or without extension to splenic and superior mesenteric veins, has been increasingly recognized in clinical practice, due to its negative impact on the outcomes of patients. 1,2 It is often associated with liver cirrhosis and abdominal malignancy. 3 By comparison, isolated splenic vein thrombosis (ISVT) without involvement of portal vein and superior mesenteric vein is usually observed in patients with pancreatic diseases, especially pancreatitis and pancreatic cancer. 4,5 This is because the splenic vein lies posterior to the pancreas and extends along the tail and neck. More than half of the patients with ISVT present with abdominal pain, followed by gastric variceal bleeding. 1 Splenectomy is often performed in the majority of ISVT patients. 6 Notably, ISVT in the absence of pancreatic diseases has been rarely reported yet. Herein, we report a case of ISVT secondary to oral contraceptives (OCs) without a history of pancreatic diseases who received anticoagulation combined with systemic thrombolysis. A 40-year-old female patient presented with left abdominal pain accompanied by diarrhea for one week at our department on August 9, 2023. She did not have hematochezia. She had no history of serious comorbidities or pancreatic diseases but took oral contraceptives (drospirenone 3mg and ethinylestradiol 0.03mg) daily during the past three months. She has no history of smoking. Contrast-enhanced computer tomography (CECT) scans showed unenhanced lesions in the splenic vein, suggesting a diagnosis of ISVT (Figure 1A). Laboratory tests showed that D-dimer level was 2.02mg/L (reference range: 0.00–0.55mg/L). She had consulted with a vascular interventionalist before our admission, and was given oral rivaroxaban. After our admission, antithrombin III, plasma protein C activity, plasma protein S activity, kappa chain, lambda chain, antiphospholipid syndrome antibody, and thrombelastography (TEG) profile were within their reference ranges. Meanwhile, she continued to receive oral rivaroxaban. On August 11, 2023, she underwent upper gastrointestinal endoscopy showing superficial gastritis without gastroesophageal varices (Figure 2A and B). On August 14, 2023, CECT scans were performed again, still showing low-density lesions in the proximal splenic vein (Figure 1B). Laboratory tests showed that D-dimer level was 1.06mg/L and R value was 4.6min (reference range: 5–10min). Plasminogen activator inhibitor type 1 gene test showed 4G/4G homozygous mutation. At this time, abdominal pain alleviated, but ISVT remained. Thus, she was informed about the efficacy and safety of thrombolysis. After that, she agreed to receive systemic thrombolysis with continuous intravenous injection of urokinase 500000u every 12 hours for a duration of 7 days. During the period of systemic thrombolysis, she did not develop any bleeding event. On August 22, 2023, abdominal pain disappeared, and CECT scans were repeated, showing a slight decrease in thrombus extension (Figure 1C). She was discharged with long-term use of oral rivaroxaban. On September 26, 2023, D-dimer level was 0.19mg/L, and CECT scans showed that the splenic vein became fibrotic c -Abstract Truncated-
obstetrics & gynecology